Bank of New York Mellon’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$43M Buy
542,454
+27,837
+5% +$2.09M 0.01% 1165
2026
Q1
$38.6M Sell
514,617
-23,269
-4% -$1.84M 0.01% 1148
2025
Q4
$42.6M Buy
537,886
+5,772
+1% +$435K 0.01% 1102
2025
Q3
$34.8M Buy
532,114
+4,926
+0.9% +$241K 0.01% 1228
2025
Q2
$20.8M Sell
527,188
-17,445
-3% -$571K ﹤0.01% 1492
2025
Q1
$16.4M Sell
544,633
-71,438
-12% -$2.34M ﹤0.01% 1601
2024
Q4
$21.5M Buy
616,071
+5,178
+0.8% +$194K ﹤0.01% 1523
2024
Q3
$24.5M Buy
610,893
+13,414
+2% +$624K ﹤0.01% 1461
2024
Q2
$28.5M Buy
597,479
+13,890
+2% +$570K 0.01% 1372
2024
Q1
$25.3M Sell
583,589
-57,474
-9% -$2.74M ﹤0.01% 1440
2023
Q4
$32.4M Buy
641,063
+13,904
+2% +$666K 0.01% 1330
2023
Q3
$28.4M Buy
627,159
+69,405
+12% +$2.86M 0.01% 1344
2023
Q2
$22.9M Sell
557,754
-8,341
-1% -$321K ﹤0.01% 1466
2023
Q1
$20.2M Sell
566,095
-7,703
-1% -$289K ﹤0.01% 1536
2022
Q4
$21.7M Sell
573,798
-5,615
-1% -$236K ﹤0.01% 1485
2022
Q3
$25.6M Sell
579,413
-85,903
-13% -$3.62M 0.01% 1353
2022
Q2
$24.6M Buy
665,316
+116,069
+21% +$4.38M 0.01% 1428
2022
Q1
$20.3M Sell
549,247
-7,330
-1% -$240K ﹤0.01% 1670
2021
Q4
$16.9M Sell
556,577
-3,989
-0.7% -$126K ﹤0.01% 1818
2021
Q3
$18.8M Buy
560,566
+20,037
+4% +$755K ﹤0.01% 1757
2021
Q2
$21.6M Sell
540,529
-4,569
-0.8% -$179K ﹤0.01% 1690
2021
Q1
$24.5M Sell
545,098
-24,896
-4% -$1.39M 0.01% 1588
2020
Q4
$32.2M Buy
569,994
+22,638
+4% +$1.13M 0.01% 1330
2020
Q3
$26M Sell
547,356
-7,705
-1% -$428K 0.01% 1299
2020
Q2
$32.7M Buy
555,061
+1,091
+0.2% +$60.7K 0.01% 1138
2020
Q1
$26.2M Sell
553,970
-19,804
-3% -$1.1M 0.01% 1129
2019
Q4
$34.7M Buy
573,774
+26,539
+5% +$1.58M 0.01% 1214
2019
Q3
$32.8M Buy
547,235
+1,800
+0.3% +$117K 0.01% 1216
2019
Q2
$35.1M Buy
545,435
+26,378
+5% +$1.86M 0.01% 1195
2019
Q1
$42.1M Sell
519,057
-11,225
-2% -$724K 0.01% 1067
2018
Q4
$28.7M Buy
530,282
+2,380
+0.5% +$121K 0.01% 1250
2018
Q3
$27.2M Buy
527,902
+8,741
+2% +$411K 0.01% 1424
2018
Q2
$21.6M Sell
519,161
-23,086
-4% -$1.02M 0.01% 1553
2018
Q1
$23.9M Buy
542,247
+1,370
+0.3% +$69.6K 0.01% 1447
2017
Q4
$27.2M Buy
540,877
+1,430
+0.3% +$78.4K 0.01% 1394
2017
Q3
$27.3M Buy
539,447
+11,447
+2% +$600K 0.01% 1376
2017
Q2
$26.9M Sell
528,000
-1,657
-0.3% -$77.2K 0.01% 1357
2017
Q1
$21.3M Buy
529,657
+10,967
+2% +$493K 0.01% 1513
2016
Q4
$24.8M Buy
518,690
+30,821
+6% +$1.22M 0.01% 1403
2016
Q3
$17.9M Sell
487,869
-73,966
-13% -$2.31M 0.01% 1525
2016
Q2
$13.1M Sell
561,835
-3,336
-0.6% -$108K ﹤0.01% 1699
2016
Q1
$22.9M Buy
565,171
+6,171
+1% +$251K 0.01% 1320
2015
Q4
$34.6M Buy
559,000
+393
+0.1% +$21.2K 0.01% 1042
2015
Q3
$22.6M Sell
558,607
-1,621
-0.3% -$83.9K 0.01% 1349
2015
Q2
$32.2M Sell
560,228
-210,001
-27% -$13.4M 0.01% 1164
2015
Q1
$49M Buy
770,229
+55,779
+8% +$3.78M 0.01% 910
2014
Q4
$44.1M Sell
714,450
-12,225
-2% -$603K 0.01% 958
2014
Q3
$28.2M Sell
726,675
-2,658
-0.4% -$94.2K 0.01% 1211
2014
Q2
$25.1M Buy
729,333
+55,628
+8% +$1.75M 0.01% 1327
2014
Q1
$29.1M Buy
673,705
+21,043
+3% +$1.02M 0.01% 1229
2013
Q4
$26M Sell
652,662
-503
-0.1% -$17.9K 0.01% 1297
2013
Q3
$24.5M Sell
653,165
-1,540
-0.2% -$46K 0.01% 1273
2013
Q2
$17.6M Buy
+654,705
New +$13.9M 0.01% 1461

Other funds holding IONS

Bank of New York Mellon's IONS Position: Q2 2026 in Review

Bank of New York Mellon increased its Ionis Pharmaceuticals (IONS) stake by 5.4% in Q2 2026, buying an estimated $2.09M and bringing the position to 542,454 shares worth $43M. The position accounts for 0.01% of the portfolio, ranked #1165.

Bank of New York Mellon first reported a position in IONS in Q2 2013 and has held it in 53 quarters since. The position peaked at $49M in Q1 2015. 241 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Bank of New York Mellon held 542,454 shares of Ionis Pharmaceuticals worth $43M as of Q2 2026.
  • Bank of New York Mellon bought 27,837 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.09M.
  • Ionis Pharmaceuticals made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1165 holding.
  • Bank of New York Mellon first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's Ionis Pharmaceuticals position peaked at $49M in Q1 2015.
  • 241 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.